Quantitative evaluation of p16INK4a promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma

Leukemia Research

Volumn 35, Issue 4, 2011, Pages 438-443

  Zainuddin, Norafiza ^a   Kanduri, Meena ^a   Berglund, Mattias ^a   Lindell, Monica ^b   Amini, Rose Marie ^a   Roos, Göran ^c   Sundström, Christer ^a   Enblad, Gunilla ^a   Rosenquist, Richard ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Diffuse large B cell lymphoma; Hypermethylation; Methylation specific PCR; P16INK4a; Pyrosequencing

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE FUNCTION; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PYROSEQUENCING; SURVIVAL RATE; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 79952362495     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.10.001     Document Type: Article

References (32)

1. Anderson J.R., Armitage J.O., Weisenburger D.D. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998, 9(July (7)):717-720.
2. Gronbaek K., de Nully Brown P., Moller M.B., Nedergaard T., Ralfkiaer E., Moller P., et al. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia 2000, 14(October (10)):1727-1735.
3. Gronbaek K., Worm J., Ralfkiaer E., Ahrenkiel V., Hokland P., Guldberg P. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. Blood 2002, 100(August (4)):1430-1437.
4. Sanchez-Beato M., Saez A.I., Navas I.C., Algara P., Sol Mateo M., Villuendas R., et al. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol 2001, 159(July (1)):205-213.
5. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366(December (6456)):704-707.
6. Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85(April (1)):27-37.
7. Herman J.G., Merlo A., Mao L., Lapidus R.G., Issa J.P., Davidson N.E., et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995, 55(October (20)):4525-4530.
8. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995, 1(July (7)):686-692.
9. Baur A.S., Shaw P., Burri N., Delacretaz F., Bosman F.T., Chaubert P. Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood 1999, 94(September (5)):1773-1781.
10. Gonzalez-Zulueta M., Bender C.M., Yang A.S., Nguyen T., Beart R.W., Van Tornout J.M., et al. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995, 55(October (20)):4531-4535.
11. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349(November (21)):2042-2054.
12. Amara K., Trimeche M., Ziadi S., Laatiri A., Hachana M., Korbi S. Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol 2008, 19(October (10)):1774-1786.
13. Garcia M.J., Martinez-Delgado B., Cebrian A., Martinez A., Benitez J., Rivas C. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-positive non-Hodgkin's lymphomas. Am J Pathol 2002, 161(September (3)):1007-1013.
14. Lee S.M., Lee E.J., Ko Y.H., Lee S.H., Maeng L., Kim K.M. Prognostic significance of O6-methylguanine DNA methyltransferase and p57 methylation in patients with diffuse large B-cell lymphomas. APMIS 2009, 117(February (2)):87-94.
15. Pinyol M., Cobo F., Bea S., Jares P., Nayach I., Fernandez P.L., et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998, 91(April (8)):2977-2984.
16. Shiozawa E., Takimoto M., Makino R., Adachi D., Saito B., Yamochi-Onizuka T., et al. Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group. Leuk Res 2006, 30(July (7)):859-867.
17. Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G. p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 1998, 91(March (5)):1680-1687.
18. Villuendas R., Sanchez-Beato M., Martinez J.C., Saez A.I., Martinez-Delgado B., Garcia J.F., et al. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol 1998, 153(September (3)):887-897.
19. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93(September (18)):9821-9826.
20. Dupont J.M., Tost J., Jammes H., Gut I.G. De novo quantitative bisulfite sequencing using the pyrosequencing technology. Anal Biochem 2004, 333(October (1)):119-127.
21. Colella S., Shen L., Baggerly K.A., Issa J.P., Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003, 35(July (1)):146-150.
22. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K., Cleary M.L., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84(September (5)):1361-1392.
23. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103(January (1)):275-282.
24. Kang S., Kim J., Kim H.B., Shim J.W., Nam E., Kim S.H., et al. Methylation of p16INK4a is a non-rare event in cervical intraepithelial neoplasia. Diagn Mol Pathol 2006, 15(June (2)):74-82.
25. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(September (30))987-94.
26. Gonzalez-Paz N., Chng W.J., McClure R.F., Blood E., Oken M.M., Van Ness B., et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007, 109(February (3)):1228-1232.
27. Hutter G., Scheubner M., Zimmermann Y., Kalla J., Katzenberger T., Hubler K., et al. Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma. Genes Chromosomes Cancer 2006, 45(February (2)):203-210.
28. Min K.O., Seo E.J., Kwon H.J., Lee E.J., Kim W.I., Kang C.S., et al. Methylation of p16(INK4A) and p57(KIP2) are involved in the development and progression of gastric MALT lymphomas. Mod Pathol 2006, 19(January (1)):141-148.
29. Tagawa H., Suguro M., Tsuzuki S., Matsuo K., Karnan S., Ohshima K., et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 2005, 106(September (5)):1770-1777.
30. Lenz G., Wright G.W., Emre N.C., Kohlhammer H., Dave S.S., Davis R.E., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008, 105(September (36)):13520-13525.
31. Garcia-Sanz R., Gonzalez M., Vargas M., Chillon M.C., Balanzategui A., Barbon M., et al. Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas. Leukemia 1997, 11(November (11)):1915-1920.
32. Huang Y., Pastor W.A., Shen Y., Tahiliani M., Liu D.R., Rao A. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS ONE 2010, 5(1):e8888.